Deutsche Bank Research rates Novartis a Buy - analysis by financial experts

Deutsche Bank Research rates Novartis a Buy - analysis by financial experts

According to a report by www.boerse.de, Deutsche Bank Research has left the rating for Novartis at “Buy” with a price target of 110 francs. The pharmaceutical company had a mixed end to the year, wrote analyst Emmanuel Papadakis in a study available on Friday. The solid outlook for 2024 is a silver lining on the horizon.

Novartis has struggled with various challenges in recent years, including the expiration of some patents and increasing competition from generics. Still, the company gave a solid outlook for 2024, which has kept investors positive. This could have a positive impact on the market and the industry, particularly in terms of investor confidence and share price performance.

In addition, Novartis' forecasts could also have a positive impact on consumers, as the company could continue to invest in research and development of new drugs. This would allow innovative treatments to be developed and brought to market, which would ultimately benefit consumers.

Overall, Deutsche Bank Research's assessment suggests that despite the challenges, Novartis is optimistic about the future and that this can have positive effects on the market, consumers and the industry.